NCATS’ Rutter: bringing ‘more treatments to all people more quickly’

The pandemic experience has turned biopharma leaders into believers in public-private partnerships, decentralized trials, master protocols and the importance of clinical trial diversity — concepts NIH’s NCATS has been advocating since it was created in 2011.

The National Center for Advancing Translational Sciences wants to leverage enthusiasm for these ideas to energize its ongoing initiatives to create and enhance platforms that can increase the efficiency of drug development so more patients benefit from scientific advances, Joni Rutter, who was appointed director of the center on Nov. 6, told BioCentury. ...